Celyad commences Phase I trial of CYAD-01 to treat colorectal cancer

Belgian biopharmaceutical firm Celyad has commenced a Phase I clinical trial (SHRINK) of its product candidate CYAD-01 (CAR-T NKG2D) for the treatment of patients with metastatic colorectal cancer.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news